Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis
Condition: Breast Cancer Intervention: Drug: Disitamab Vedotin plus pyrotinib or naratinib Sponsor: Xi'an International Medical Center Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Hospitals | Neurology | Research